Q4 2023 BioInvent International AB Earnings Call Transcript
Welcome to the BioInvent Q4 Report 2023 Conference Call. (Operator Instructions) Now I will hand the conference over to the speakers: CEO Martin Welschof, CFO Stefan Ericsson. Please go ahead.
Yes, welcome, everybody, to our year-end report. And we will guide you through a number of slides. First, I will give you a summary of what has happened with some focus areas. And then at the end, Stefan Ericsson, the CFO, will give you the financials. And I am the CEO, Martin Welschof.
So we'll start on slide number 3, where we have a summary of the main events in the fourth quarter. And I would like to start with our program, BI-1808, which is our lead program targeting TNF receptor 2. And we had very interesting, positive data from the clinical Phase 1/2a, which is currently ongoing, where we test the antibody, BI-1808, as a single agent. And we presented that at SITC. And I will come back to the data a little bit later. Then we also have shown preclinical data providing clear evidence of the potential of our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
